MannKind adds Furoscix heart-failure drug via $325M debt-funded acquisition, warns United Therapeutics may deprioritize key royalty product

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Acquired scPharma in Oct 2025, adding Furoscix (FDA-approved subcutaneous diuretic for heart failure) with $20.9M gross revenue in Q1 2026. Funded by new $325M Blackstone facility at 9.09% rate, replacing prior $36.3M convertible notes at 2.50%.

  MD&A: Furoscix acquisition and Blackstone Credit Facility verify on EDGAR →
• high

  New risk factor warns United Therapeutics may shift commercial focus from Tyvaso DPI (MannKind's largest royalty source) to competing products Yutrepia and Tresmi, citing UT's Feb 2026 earnings call statements prioritizing pipeline over current products.

  Risk Factors: United Therapeutics commercial emphasis verify on EDGAR →
• high

  Net commercial sales rose 79% to $33.9M (driven by Furoscix), but SG&A expenses more than doubled to $54.1M and interest expense jumped 61% to $7.5M, reflecting acquisition integration costs and higher debt service.

  MD&A: Revenue and operating expenses verify on EDGAR →